Summary
Becton, Dickinson and Company (BD) announced the resumption of shipments for its ChloraPrep™ product in the U.S. This follows a voluntary ship hold initiated on May 6, 2026, for ChloraPrep™ and PurPrep™ while the company conducted additional final release testing. The company has stated that all subsequent testing has been acceptable and, importantly, there have been no reported patient safety signals associated with these products. This action is a direct response to a Warning Letter received from the FDA concerning the El Paso manufacturing facility. While the immediate concern regarding product shipment has been addressed with acceptable testing results, investors should note that the underlying issues related to the El Paso Warning Letter remain. BD directs stakeholders to their Form 10-Q for the quarter ended March 31, 2026, for a detailed description of the Warning Letter and associated risks, as well as their latest 10-K and other SEC filings for forward-looking statement disclaimers.
Key Highlights
- 1BD has resumed U.S. shipments of ChloraPrep™.
- 2The ship hold was initiated on May 6, 2026, for ChloraPrep™ and PurPrep™ due to additional final release testing requirements.
- 3All additional final release testing for ChloraPrep™ has been deemed acceptable.
- 4No patient safety signals have been reported in connection with these products.
- 5The ship hold was a proactive measure in response to an FDA Warning Letter for the El Paso manufacturing facility.
- 6Investors are advised to review BD's Form 10-Q for the quarter ended March 31, 2026, for details on the El Paso Warning Letter and associated risks.